Ongoing Clinical Trials Look to Assess Optimization or Combination Treatments of Asciminib in CML

Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, discusses ongoing trials assessing efficacy and safety of asciminib in the treatment of chronic myeloid leukemia.

Pharmacy Times interviewed Myriam Mendila, MD, chief medical officer and global head of medical affairs at Novartis Oncology, on her presentation at the 63rd American Society of Hematology Annual Meeting & Exposition on new longer-term efficacy and safety data from the pivotal phase 3 ASCEMBL study for FDA-approved asciminib.

During the interview, Mendila discussed ongoing trials assessing efficacy and safety of asciminib in the treatment of chronic myeloid leukemia.

Related Content:

ASHOncologyConferenceHospitalSpecialty Pharmacy
Researchers Explore More Safe and Effective CAR T-Cell Therapy for Cancer Treatment
Targeted Therapies Could Be Key to Treating Myelodysplastic Syndrome
Researchers Explore Approaches to Block T-Cell Exhaustion